{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-24-000025","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.079803+00:00","generated_at":"2026-06-03T07:20:39.037650+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance","bullets":["Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.","Net sales $695.4M, down 3.0% organically; Proprietary Products sales down 4.0%.","Full-year 2024 net sales guidance reaffirmed at $3.000-3.025B; adjusted EPS guidance raised to $7.63-7.88 from $7.50-7.75.","Board declares Q3 dividend $0.20/share, payable Aug 7, 2024 to holders of record Jul 31.","Repurchased 729,679 shares for $267M at avg $365.87 in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-24-000025","json":"https://secwatch.observer/filing/0000105770-24-000025.json","markdown":"https://secwatch.observer/filing/0000105770-24-000025.md","text":"https://secwatch.observer/filing/0000105770-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/wst-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:20:39.037650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9448abb4b5cefd0c55ddb4f2764ea4be12ec54f7","claim":"WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2024 results: revenue 695.4 million, EPS 1.55.","evidence_excerpt":"Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%. • Reported-diluted EPS of $1.55 declined by 16.2%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first-quarter 2024"},{"label":"Revenue","value":"695.4 million"},{"label":"EPS","value":"1.55"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}